Belgian Semiconductors Stock News

UCB (ENXTBR:UCB) just shared results from a multicenter study published in Neurology, highlighting that a new investigational therapy for TK2 deficiency showed some treated patients needed less ventilatory support, with mostly mild side effects. See our latest analysis for UCB. Despite some recent pullbacks, UCB’s share price has surged with a 22.5% gain over the past month and a remarkable 42.2% in the last 90 days. Momentum appears to be on the upswing, and when you look at the long game,...

VGP has acquired the 280,000 square metre former Kabel Premium Pulp & Paper factory site in Hagen, Germany, from insolvency proceedings, with plans to transform it into a modern business and industrial park focused on sustainability and EU Taxonomy compliance. This redevelopment marks VGP's entry into a prime logistics and industrial hub near Dortmund, supported by close collaboration with local authorities and access to established infrastructure. Let's examine how VGP's move to promote...

argenx (ENXTBR:ARGX) is generating buzz after announcing pivotal ADAPT SERON results and interim findings from the ADAPT Jr study at major neuromuscular conferences. These presentations highlight progress in treating difficult myasthenia gravis cases. See our latest analysis for argenx. argenx’s wave of new data and high-profile conference presentations has clearly fueled buying momentum. The stock’s share price has jumped 44.7% over the past three months, and its total shareholder return is...

In the past week, Solvay SA reported a year-over-year drop in second-quarter 2025 earnings, with both underlying net sales and EBITDA affected by difficult market conditions. An interesting development is Solvay's achievement of €29 million in cost savings during the quarter while pressing ahead with rare earth and soda ash projects intended to reinforce its market standing. We'll explore how Solvay's ongoing focus on operational efficiency and cost-saving progress informs its investment...

argenx SE recently presented new data for VYVGART® and its efgartigimod pipeline at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session in San Francisco. These clinical updates, which include pivotal trial and real-world data across multiple patient subgroups, highlight advances in treating generalized myasthenia gravis and support ongoing innovation in rare neuromuscular...

With a price-to-earnings (or "P/E") ratio of 6x Etex N.V. ( EBR:094124453 ) may be sending very bullish signals at the...

As the pan-European STOXX Europe 600 Index recently experienced a dip following record highs, investor sentiment has been influenced by political turmoil in France and international trade tensions. Amidst this backdrop, small-cap stocks often present unique opportunities for growth due to their agility and potential to capitalize on niche markets and emerging trends.

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...

D'Ieteren Group SA ( EBR:DIE ), is not the largest company out there, but it saw significant share price movement...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But its...

Solvay (ENXTBR:SOLB) has drawn fresh attention after releasing its latest quarterly results, which revealed lower sales and EBITDA. The company is addressing these challenges through cost-saving initiatives and ongoing investments in key projects. See our latest analysis for Solvay. Solvay’s recent quarterly results arrived alongside a notable jump in the share price, with a single-day gain of over 5%. Still, its year-to-date share price return sits at -7.4%, and the one-year total...

When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 15x, you may consider Elia...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...

Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...

Umicore SA ( EBR:UMI ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Looking...

Fagron (ENXTBR:FAGR) continues to attract attention among healthcare investors, with its share price seeing modest gains this week. Its long-term performance offers interesting insights for those weighing growth in the sector. See our latest analysis for Fagron. Fagron’s share price has pushed up 25.3% year-to-date, reflecting investor optimism after a steady stream of operational improvements. With a 12.6% total shareholder return in the last year and an impressive 92% gain over three...

If you are weighing your next move with argenx stock, you are definitely not alone. After all, this is a company that has rewarded patience. Just looking at the numbers, argenx has surged 41.0% in the past year and an incredible 195.9% over five years. Even in the shorter term, the momentum is hard to ignore, with a 1.0% gain over the past week and a solid 4.5% for the month. With returns like these, it is no wonder there is so much buzz around what is driving the growth, how much upside...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

In late September 2025, Anheuser-Busch announced a US$7.4 million investment to upgrade brewing and packaging equipment at its Los Angeles brewery to boost Michelob ULTRA production in response to demand for new can sizes and formats as part of its wider “Brewing Futures” initiative, with over US$300 million earmarked for U.S. operations. This investment, along with a US$9 million expansion for Beyond Beer products in New York, highlights AB InBev’s focus on supporting manufacturing jobs,...

UCB Pharma and Tanner Pharma Group recently announced a partnership aimed at enabling greater access to innovative treatments for epilepsy patients across Southeast Asia. This collaboration is significant as it may help UCB tap into new markets with high unmet medical needs, supporting their ambitions for global growth in specialty biopharma. With UCB expanding patient access through this new partnership, we’ll examine how such geographic growth could influence the company’s broader...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Readers hoping to buy Melexis NV ( EBR:MELE ) for its dividend will need to make their move shortly, as the stock is...